About 15 % of all couples experience infertility at some time during their reproductive lives. Nowadays, infertility can be treated by the use of assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). A common element of these programs is the treatment with follicle-stimulating hormone (FSH) to increase the number of oocytes retrievable for the IVF or ICSI procedure (multifollicular development). Patients suffering from female infertility because of chronic anovulation may also be treated with FSH, then with the aim to achieve monofollicular development.
KeywordsLuteinizing Hormone Assisted Reproductive Technology Chinese Hamster Ovary Cell Line Prefilled Syringe International Nonproprietary Name
- Devroey P, Boostanfar R, Koper NP, Jzerman PI, Mannaerts BMJL, Fauser BC, for the ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072Google Scholar
- European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 18, 11-April 2011. European Agency for the Evaluation of Medicinal ProductsGoogle Scholar
- Van Wezenbeek P, Draaier J, Van Meel F, Olyve W (1990) Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In: Crommelin DJA, Schellekens H (eds) From clone to clinic developments in biotherapy, vol I. Kluwer, Dordrecht, pp 245–251CrossRefGoogle Scholar
- Mannaerts BMJL (2013) Innovative drug development for infertility therapy, Ph.D. thesis, Utrecht, The Netherlands, ISBN 978-90-393-5939-6Google Scholar